[12] Patent
[11] Patent No.:GC0007569  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126002
Date of the Decision to Grant the Patent:15/Apr/2018

[21] Application No.:GC 2013-23882

[22] Filing Date:23/3/2013

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
US
3/4/2012
14/9/2012
31/1/2013
61/619,460
61/700,960
61/758,798

[72] Inventors:1- James Peter BECK،2- Steven James GREEN،3- Jose Eduardo LOPEZ،4- Brian Michael MATHES،5- Dustin James MERGOTT،6- Zoran RANKOVIC،7- Warren Jaye PORTER،8- Yuan SHI،9- Brian Morgan WATSON،10- Leonard Larry WINNEROSKI JR

[73] Owner: Eli Lilly And Company, Lilly Corporate Center, Indiana 46206-6288, Indianapolis, USA

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: A61K 31/407; A61P 25/28; C07D 513/04 (2006.01)

[56] Cited Documents:

-US 2009/209755 A1 (SUZUKI YUICHI [JP] ET AL) 20 August 2009
-EP 2 151 435 A1 (SHIONOGI & co [JP]) 10 February 2010
 
Examiner: PH. Sultana K. AlOudah

[54] TETRAHYDROPYRROLOTHIAZINE COMPOUNDS
[57] Abstract: The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; R1 is H or F; R2 is H, –CH2OH, C1-C3 alkyl, ; R3 is H, F, or CN; R4 is H, F; or CN; and R5 is H, –CH3, or –OCH3; or a pharmaceutically acceptable salt thereof.
No. of claims: 15


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.